Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IGC Pharma's Enterprise Value is $29.99 Mil.
IGC Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.67 Mil. Therefore, IGC Pharma's EV-to-EBIT ratio for today is -2.57.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, IGC Pharma's Enterprise Value is $29.99 Mil.
IGC Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.04 Mil. Therefore, IGC Pharma's EV-to-EBITDA ratio for today is -2.72.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, IGC Pharma's Enterprise Value is $29.99 Mil.
IGC Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.22 Mil. Therefore, IGC Pharma's EV-to-Revenue ratio for today is 24.67.
IGC Pharma Enterprise Value Historical Data
The historical data trend for IGC Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IGC Pharma's Enterprise Value
For the Biotechnology subindustry, IGC Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Enterprise Value falls into.
IGC Pharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
IGC Pharma's Enterprise Value for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (AMEX:IGC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
IGC Pharma's current Enterprise Value is $29.99 Mil.
IGC Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.67 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
IGC Pharma's current Enterprise Value is $29.99 Mil.
IGC Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.04 Mil.
IGC Pharma's current Enterprise Value is $29.99 Mil.
IGC Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGC has been successfully added to your 